APRE
Aprea Therapeutics, Inc.
1W: +3.9%
1M: -6.5%
3M: -16.0%
YTD: -10.4%
1Y: -67.6%
3Y: -85.3%
5Y: -99.4%
$0.76
-0.00 (-0.17%)
After Hours: $0.75 (-0.01, -1.54%)
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$5.0M
52W Range0.548-2.442
Volume89,894
Avg Volume2,210,147
Beta1.43
Dividend—
Analyst Ratings
Company Info
CEOOren Gilad
Employees8
SectorHealthcare
IndustryBiotechnology
IPO Date2019-10-03
Websiteatrinpharma.com
535 Boylston St.
Boston, MA 02116
US
Boston, MA 02116
US
617-463-9385
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Latest News
Analysts Issue Forecasts for APRE Q1 Earnings
Aprea Therapeutics GAAP EPS of -$0.32 beats by $0.07
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
12 Health Care Stocks Moving In Tuesday's After-Market Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Gilad Oren | A-Award | 20,175 | — | 2026-03-12 |
| Gilad Oren | A-Award | 80,700 | $0.77 | 2026-03-12 |
| Hamill John P. | A-Award | 10,095 | — | 2026-03-12 |
| Hamill John P. | A-Award | 40,380 | $0.77 | 2026-03-12 |
| Gilad Oren | P-Purchase | 28,100 | $0.89 | 2026-01-30 |